Alberta Investment Management Corp purchased a new stake in InMode Ltd. (NASDAQ: INMD) during the third quarter, according to its most recent filing with the SEC. The fund purchased 195,417 shares of the healthcare company's stock, valued at approximately $2,769,000. Alberta Investment Management Corp owned about 0.34% of InMode as of its most
InMode has seen revenue decline 1.2% Y/Y in Q3, with U.S. demand weak but international gains providing some offset. Management reaffirmed FY26 guidance and holds $512.7 million in cash, but margins have declined due to deliberate investments post-restructuring. Takeover drama has ended, shifting focus to operational stabilization, international expansion, and prudent cash deployment.
YOKNEAM, Israel, Nov. 11, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter of 2026.
NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), a significant, long-standing shareholder of InMode Ltd. (“InMode” or the “Company”) (Nasdaq: INMD), today issued an open letter to all InMode stakeholders. The full text of the letter is below. October 19, 2026 To All InMode Stakeholders: Steel Partners Holdings L.P. (together with its affiliates, “Steel”) is a significant, long-standing shareholder of InMode Ltd. On July 9, 2026, we proposed to acq.
YOKNEAM, Israel, Oct. 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2026 before the Nasdaq market opens on Wednesday, November 11, 2026.
PAVmed (NASDAQ: PAVM - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings. Valuation and Earnings This table compares PAVmed and InMode"s
InMode remains rangebound as US platform sales decline, but international growth and recurring consumables revenue provide stabilization. I maintain a 'buy' rating, downgraded from 'strong buy,' citing cyclical industry softness, macro headwinds, and management's capital allocation frustrations. INMD's robust net cash (~$497M), aggressive buybacks, and proprietary technology underpin a strong moat, yet sentiment is hampered by leadership doubts and execution risk.
LogicMark (OTCMKTS:LGMKD - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Risk and Volatility LogicMark has a beta of 1.67,
InMode (NASDAQ: INMD - Get Free Report) and IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Risk and Volatility InMode has a beta of 1.86,
IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- InMode Ltd.